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Summary 
Interleukin (IL)-6, IL-113, and tumor necrosis factor 0r  (TNF-ot) are considered to act as endog- 
enous pyrogens. Because of the complex pattern of cross-inductions between these cytokines, 
the relative  role of the central and peripheral production of these cytokines in eliciting the fe- 
ver response has not yet been clarified.  The purpose of this study was to determine the role of 
IL-6 in the fever response by making use  of mice carrying a null mutation in the IL-6 gene. 
The intraperitoneal injections oflipopolysaccharide (LPS) (50 bLg/kg) and recombinant murine 
(rm)  IL-113 (10  b~g/kg),  respectively,  failed  to  evoke fever response  in  IL-6-deficient mice, 
whereas the same doses of LPS and rmIL-113 caused fever response in wild-type mice. The fe- 
ver response could be induced in the IL-6-deficient mice by intracerebroventricular injection 
of recombinant human (rh) IL-6 (500 ng/mouse), whereas intracerebroventricular injection of 
rmlL-113  (100  ng/mouse) failed  to produce fever response in the  IL-6-deficient mice.  These 
results suggest that central IL-6 is a necessary  component of the fever response to both endoge- 
nous (IL-113) and exogenous (LPS) pyrogens in mice and that IL-6 acts downstream from both 
peripheral and central IL-113. 
F 
ever  is  a  systemic  response  that  can  be  elicited  by  a 
multitude of exogenous stimuli (1-4). Work in the past 
decade has  led  to identification  of several  of the  endoge- 
nous mediators of fever.  IL-lex and  IL-113 (5,  6),  TNF-e~ 
(7), and IL-6 (6, 8-13) have been identified as putative en- 
dogenous pyrogens, based on experiments that showed that 
systemic  or  central  intracerebroventricular  application  of 
these  cytokines evokes fever response.  In addition,  it  has 
been demonstrated that the mRNAs encoding these cyto- 
kines as well as their gene products are increased in the pe- 
riphery (14,  15)  and, more importantly, in some brain re- 
gions, including the hypothalamus, during fever caused by 
injection of bacterial  LPS (16-19). Receptors for these cy- 
tokines  are  also  found in the  thermoregulatory regions  of 
the brain, such as the preoptic area of the hypothalamus (4, 
20-22). 
IL-6, a proinflammatory cytokine (8), acts as an endoge- 
nous pyrogen (6, 8-13) in addition to its multiple effects on 
the immune system and in particular on hematopoiesis (8). 
The major inducers of IL-6 synthesis  are IL-1 and TNF-o~, 
which also act as  inducers  of each other's biosynthesis (7, 
15,  16, 23-25). The study of the complex cascade  oflL-1, 
TNF-c~, and IL-6 effects is difficult  because no reliable  an- 
tagonists  exist  for  TNF-cx  and  IL-6,  respectively;  some 
TNF-oL antagonists  (26) as well as some antagonists  of hu- 
man  IL-6  (27) but  not  of murine  IL-6 action  have  been 
described. 
Recently, we generated a strain  of mice carrying a null 
mutation in the IL-6 gene, and therefore defective in IL-6 
production (28).  These mice (28, 29)  represent a powerful 
tool to characterize unambigously the role of IL-6 in sev- 
eral physiological and pathological phenomena. 
IL-6-deficient mice  are  unable  to  mount a  normal in- 
flammatory response  to localized tissue  damage generated 
by turpentine injection (30) but show no altered metabolic 
and lethality responses  to TNF-er  (31) and LPS (30). 
In this article,  we examine the fever response to the ex- 
ogenous pyrogen LPS and the endogenous pyrogen IL-113 
in IL-6-deficient mice and in wild-type littermates  to de- 
fine the role played by IL-6 in the pyrogenic response.  To 
elucidate the  role  of peripheral  and central pools of IL-6, 
which  does  not  readily  cross  the  blood-brain barrier,  we 
have  used  both  systemic  (intraperitoneal)  and  intracere- 
broventricular injection of IL-6 to restore fever response in 
IL-6-deficient mice. 
Materials  and Methods 
Materials.  LPS from Escherichia coli (055:B5, purified by phe- 
nol extraction and gel filtration chromatography) was from Sigma 
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all experiments. Recombinant murine (rm) IL-113 was a gift from  ~  38,s 
Dr.  P.  T.  Lomedico  (Hoffman-La Koche,  Basel,  Switzerland).  ~  38 
1Kompun was from Bayer AG (Leverkusen, Germany) and Keta- 
lar was from Parke-Davis, S.A. (Barcelona, Spain). Recombinant  3z,s 
human (rh)  IL-6 was produced in E.  coli at the Institute for Re- 
search in Molecular Biology ([IRBM] Rome,  Italy) as described  ~  ~7 
by Arcone et al.  (32).  The bioactivity (2  ￿  10  ~ U/mg) was as-  >~ 
sayed using 7TD1  cell growth assay (33).  All substances were di-  g  a6,s 
luted in pyrogen-free saline solution the day of the experiment.  ~  36 
Animals.  13-18-wk-old IL-6  /- male mice and IL-6 +/+  lit- 
termates  were  bred at  IP,.BM.  The  generation of this  strain of  ~s,s 
mice and its genetic background has been described by Poli et al.  - 1 
(28).  The mice were housed one per cage in a temperature-con- 
trolled room, with food and water ad libitum and under a  12-h 
light/12 h dark diurnal cycle (light at 8.00 a.m.). The temperature 
in the room was kept at 30 -+  1~  The animals were acclimated  n 
for at least 1 wk before starting any experimental procedure. The  3a,s 
experiments started when the mice reached a body weight of 30 +  E  38 
2 g; no differences in body weight were observed between IL-6- 
deficient and wild-type mice.  ~  ~  37,s 
Measurement  of Body  Temperature.  A  radiotransmitter was in-  m~ 
serted in the mouse peritoneal cavity under anesthesia with ket-  ~  ~  37 
amine (Ketalar, 50 mg/kg) and xylazin (Rompun, 10 mg/kg). All 
mice with a radiotransmitter inserted were indistinguishable (for  ~  36,s 
their body weight and activity) from normal mice 4  d  after the  0 
36 
surgery. After implantation, the animals were allowed to recover 
for at least 5  d before starting any experimental procedure.  The  3s,s 
core body temperature and activity (data not shown) of the ani- 
mals were measured using battery-operated biotelemetry devices 
(model XM-FH;  Mini-Mitter Co.,  Inc.,  Sunriver, OK)  as  de- 
scribed by Kozak et al.  (34).  Body temperature values were  re- 
corded at 10 rain intervals beginning at least 24 h before the in- 
jection ofLPS, rmlL-l[3, or rhlL-6 and continued for at least 48 h 
after  the  injections.  All  treatments  began  between  10:00  and 
11.30 a.m., during the light period. 
Intracerebroventricular injection of 10 ptl was carried out un- 
der ether anesthesia, at the site described by Haley and McCor- 
mick (35). The needle was lowered 3.5 mm after penetration. 
Statistical Analysis.  All  data  were  reported  as  mean  +  SE. 
Analysis of variance followed by Fisher's protected least signifi- 
cant difference test was used to analyze statistical  differences. The 
average  group  size  was  five.  Animals with  consecutive missing 
temperature recordings because of failure of the telemetry system 
were excluded from the statistical  analysis. 
Results 
We  have  studied  the  circadian variations of body  tem- 
perature  in  wild-type  and  IL-6-deficient  mice,  respec- 
tively. No  difference was  observed in the  daily rhythm of 
temperature  changes  between  these  two  groups  of mice 
when kept  at 30  --  1~  (data not shown),  suggesting that 
normal regulation of body  temperature  is  not affected  by 
the absence of IL-6 expression in the mice with null muta- 
tion of the IL-6 gene. 
LPS injection (50 I~g/kg i.p.) caused a reproducible fever 
response in the wild-type mice (Fig.  1 A)  (maximal change 
in body temperature  ~-~1.4~  starting 1.5 h  after the LPS 
injection and reaching maximum after 4.5 h. No fever was 
observed  in  the  IL-6-deficient mice  (Fig.  1  B)  upon  the 
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Figure 1.  Effect  of LPS (50 I.zg/kg i.p.) or malL-1 [~ (10 btg/kg i.p.) in- 
jection on the  core body temperature  of IL-6-deficient  and wild-type 
mice measured at 30 •  1~  of ambient temperature.  Data are mean  + 
SE. ** P <0.01, saline- versus LPS-injected mice; *P <0.05, saline- ver- 
sus LPS-injected mice;  7K2)(  P <0.05, saline- versus nnlL-1]3-injected 
mice. (A) LPS (50 btg/kg i.p.) or malL-l[~ (10 p.g/kg i.p.) effects on body 
temperature  in wild-type  mice. Saline- injected mice (O; n =  6); LPS- 
injected mice (V; n =  5); and rmIL-l[3-injected mice (I; n =  5).  (B) 
LPS (50 l.tg/kg i.p.) or nnlL-1 [3 (10 l.tg/kg i.p.) effects on body tempera- 
ture  in  IL-6--deficient mice.  Saline-injected  mice  (C); n  =  5);  LPS- 
injected mice (V; n =  5); and rmlL-l[3-injected mice (K]; n =  4). 
same  LPS  treatment.  The  handling stress  caused  tempera- 
ture elevation and was present and had the same magnitude 
in the IL-6-deficient mice as in wild-type littermates. The 
injection of LPS  (50  p~g/kg i.p.)  induced in all the  IL-6- 
deficient mice (and not in the wild-type mice) a significant 
reduction  in body  temperature  (~0.5~  during the  first 
1-2.5 h  after LPS injection (36). 
The intraperitoneal injection of an endogenous pyrogen, 
rmlL-l[3  (10  p,g/kg  i.p.)  into  wild-type  mice  (Fig.  1  A) 
caused fever for at least 3 h  starting ~3  h  after the rmlL-l[3 
injection, whereas the same dose ofrmlL-l[3 did not cause 
a  fever  response  when  injected  into  the  IL-6-deficient 
mice (Fig.  1 B). Raising the dose ofrmlL-l[3 to 25  p,g/kg 
i.p.  caused  hypothermia  in  the  wild-type  mice  (data  not 
shown), indicating that this is a toxic dose, yet not even this 
larger  dose  of rmlL-l[3  evoked  any fever response  in the 
IL-6-deficient mice (data not shown). 
Injection of rhlL-6 (250 p~g/kg i.p.) alone caused no re- 
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mice  (Fig.  2,  A  and  B),  although  a  transient  hyperthermic 
period  was  observed  upon  injection  of the  IL-6-deficient 
mice with this dose of rhlL-6 (Fig. 2  B). 
To  examine whether  this peripheral  injection of rhlL-6 
could  restore  the  fever response  to  LPS  in  IL-6-deficient 
mice,  we  combined  rhIL-6  and  LPS  and  injected  these 
agents intraperitoneally.  Fig.  2  A  shows that  this combina- 
tion  of rhIL-6  (250  b~g/kg  i.p.)  and  LPS  (50  Izg/kg i.p.) 
caused a  large  (maximal change  1,8~  and  sustained  fever 
response  in wild-type mice, which was faster in onset than 
the fever response  caused by  LPS  alone  (see  Fig.  1 A)  but 
which  otherwise  closely resembles  the  LPS-induced  fever 
(see  Fig.  1  A).  In  the  IL-6-deficient  mice,  the  fever  re- 
sponse  (maximal  change  1~  to  combined  intraperitoneal 
injection of rhlL-6 and LPS was atypical in kinetics,  with- 
out a  clear peak,  and it was  significantly smaller in magni- 
tude; furthermore,  the response was also delayed (Fig. 2  B). 
The  duration  of this  fever  hyperthermia  was  also  much 
longer (8 h) than fever caused by the same treatment in the 
wild-type mice (6 h)  (Fig. 2 A). 
To study the role of centrally produced IL-6 in the fever 
response  to rmIL-113  and rhIL-6,  we carried out intracere- 
broventricular  injections  of these  two  endogenous  pyro- 
gens.  Fig.  3  A  shows  that  both  rmIL-l[3  (100  ng/mouse 
icv.)  and  rhIL-6  (500  ng/mouse  icy.),  respectively,  caused 
fever in  the  wild-type  mice.  The  maximum  fever (1.2~ 
was reached 5 h  after the injections of either of the two en- 
dogenous  pyrogens.  Injection  of rhIL-6  (500  ng/mouse 
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Figure 2.  Effects of the systemic injection  of rhlL-6 (250 ~g/kg i.p,) 
and combined LPS (50 ~g/kg i.p.)  and rhlL-6 (250 I~g/kg i.p.)  on the 
core body temperature  of IL-6~leficient and wild-type mice measured at 
30  +  o  I  C of ambient  temperature.  Data are mean +  SE. ** P <0.01  sa- 
line- versus rhlL-6-combined LPS-injected mice; * P <0.05 saline- ver- 
sus rhlL-6-combined LPS-injected mice.  (A) The effects of the systemic 
injection of rhlL-6 (250 ~g/kg i.p.) and combined LPS (50 I~g/kg i.p.) 
and  rhlL-6  (250 I~g/kg i.p.)  into wild-type mice. Saline-injected  mice 
(Q; n =  6); rhlL-6-combined saline-injected mice (A; n =  5); and rhlL- 
6-combined LPS-injected mice (0;  n =  4).  (B) The effects of the sys- 
temic injection ofrhIL-6 (250 tJtg/kg i.p.) and combined LPS (50 ~g/kg 
i.p.) and rhlL-6 (250 Ixg/kg i.p.) into IL-6-deficient mice. Saline-injected 
mice (O; n =  5); rhlL-6-combined saline-injected  mice (A; n =  4); and 
rhlL-6--combined  LPS-injected mice (~; n =  4). 
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Figure  3.  Effects of intracerebroventricular  injection of rhlL-6  (500 
ng/mouse, in 10 p,1) and rmIL-l~ (100 rig/mouse,  in 10 I.d), respectively, 
on the core body temperature  of IL-6-deficient and wild-type mice mea- 
sured at 30 •  1~  of  ambient temperature. Data are mean +  SE. ** P <0.01 
saline-  versus rhlL-6-injected mice; * P  <0.05  saline-  versus rhIL-6- 
injected  mice;  [~[~l[  P  <0.01  saline- versus rmlL-l~-injected mice; 
P <0.05  saline- versus rrnlL-113-injected  mice.  (A) The effects of 
the intracerebroventricular  injection ofrhlL-6 (500 rig/mouse,  in 10 ~1) 
and  rmlL-l~  (100 ng/mouse,  in  10  ptl), respectively,  into  wild-type 
mice. Saline-injected  mice (O; n =  6); rhlL-6-injected mice (A; n =  5); 
and rmlL-l~-injected mice (11; n =  4). (B) The effects of the intracere- 
broventricular  injection  of rhlL-6  (500 ng/kg,  in  10  ILl) and  rmlL-ll3 
(100  ng/kg,  in  10  rtl), respectively,  into  IL-6-deficient mice.  Saline- 
injected mice (C); n =  6); rhlL-6 injected mice (A; n =  5); and rmlL-l~ 
injected mice ([~; n =  4). 
313  Chai et al.  Brief Definitive Report icy.) but not ofrmlL-l[3 (100 ng/mouse icv.) caused fever 
in  the  IL-6-deficient  mice  (Fig.  3  B).  Fever  caused  by 
rhlL-6 lasted at least 9 h and reached a maximum tempera- 
ture elevation of 1.6~  The fever induced by rhlL-6 con- 
tinued  into  the  "dark period"  (when  the  core body tem- 
perature  of rodents is higher),  so that the exact time when 
the  fever peak  subsided  is  hard  to  determine,  but  on the 
next morning all of these animals had normal temperature. 
The large initial hypothermic response seen in both wild- 
type and IL-6-deficient mice is probably attributable  to the 
ether  anaesthesia  applied  in  these  intracerebroventricular 
injection experiments. 
Discussion 
Fever is one of the systemic inflammatory responses (1-4) 
that can be evoked by bacterial infection on the periphery 
or centrally.  The  ability  of peripherally  injected  bacterial 
LPS to evoke distinct and long-lasting fever peak (34)  is at- 
tributed to its  ability to induce peripheral  as well as central 
production of endogenous pyrogens such as IL-113, TNF-cL 
and IL-6 (7,  15-19) and prostaglandins (9). 
This study clearly shows that the LPS-mediated fever re- 
sponse in mice is dependent  on expression  of IL-6, as the 
IL-6-deficient mice could not mount a fever response (Fig. 
1 B),  whereas  their  wild-type litter  mates responded  with 
fever to  LPS  (Fig.  1 A).  Earlier  reports  on IL-6-deficient 
mice indicated  that,  when  injected  with  LPS,  these  mice 
produce  a normal  corticosterone  response  and a  threefold 
enlarged serum TNF-cx response  (29).  Obviously, the  ele- 
vated  serum  TNF-c~  response  to  LPS  is  not  sufficient  to 
evoke a fever in these IL-6-deficient mice. 
IL-113 is known to be a most efficient endogenous pyro- 
gen whether injected intraperitoneally  or intracerebroven- 
tricularly (5).  In wild-type mice intraperitoneal injection of 
traiL-1 [3 caused a typical fever response (Fig. 1 A), whereas 
such response was absent in the IL-6-deficient mice (Fig.  1 
B).  Thus,  it appears  that fever response  to an endogenous 
pyrogen such as IL-113 also requires  IL-6 expression.  Both 
IL-113  and  TNF-cl  are  strong inducers  of IL-6 expression 
(12,  14-16)  in  wild-type  animals,  and  thus  it  is  plausible 
that IL-6 acts downstream from these cytokines in the fever 
response. 
It  is  noteworthy  that  not  even  the  centrally  apphed 
traiL-l[3 (Fig. 3 B) caused fever in the IL-6-deficient mice, 
whereas  the same dose caused rapid and long lasting fever 
in the wild-type mice (Fig.  3 A), suggesting that brain ex- 
pression  and presence  of large  doses  of IL-113  are  insuffi- 
cient for evoking the fever response in the absence of IL-6; 
thus, IL-6 must act downstream from the central IL-113. 
To examine whether it is the central or peripheral pool 
of IL-6 that is required  in the  fever response,  we injected 
mice  with  IL-6  intraperitoneally  (Fig.  2)  and  intracere- 
broventricularly (Fig. 3). It is known that IL-6 is an endog- 
enous  pyrogen that  acts  centrally  (6,  9,  10,  16,  18).  Our 
data showing that peripheral injection of large doses of IL-6 
is unable to evoke fever response in wild-type (Fig. 2 A) as 
well  as  in  IL-6-deficient mice  (Fig.  2  B)  are in line  with 
these reports (9-13). 
In  the  IL-6-deficient  mice,  the  combination  of intra- 
peritoneal  injection  of LPS  and  rhIL-6  produced  some 
small,  atypical fever response  (Fig.  2  /3), with  slow  onset, 
which may reflect some leakage of IL-6 from the peripheral 
to the central compartment.  Cytokine transport through the 
blood-brain barrier has earlier been suggested by Banks  et 
al.  (37), and it is possible that some IL-6 transport (38) into 
the brain occurs; in addition,  clearance of IL-6 may also be 
changed in the presence  of LPS. Nevertheless,  the  lack of 
effect of intraperitoneally injected IL-6, alone and together 
with  LPS,  on the  fever response  clearly demonstrates  that 
interpretations  of results  of intracerebroventricular  injec- 
tion ofpyrogens that hold that these agents cause fever after 
having leaked from the brain to the periphery or induced a 
large response in the periphery first cannot hold for IL-6. 
The key finding of this study using IL-6-deficient mice 
is that centrally applied IL-6 causes a rapid and long-lasting 
fever response not only in wild-type (Fig. 3 A) but also in 
IL-6-deficient  mice  (Fig.  3  /3). These  data  confirm  that 
IL-6 is a centrally acting pyrogen as described earlier  (6,  9, 
16,  18),  and demonstrate  that,  in IL-6-deficient mice,  the 
IL-6 receptor-gp  130  complex was  intact  and  capable  of 
signaling.  It should be  mentioned  that  gp  130  is  used  by 
several  other  IL-6-related  cytokines  such  as  ciliary  neu- 
rotrophic factor (CNTF), leukemia-inhibitory factor, onco- 
statin M, and IL-11, which have overlapping inflammatory 
activities  (39)  and  of which  CNTF  and  leukemia-inhibi- 
tory factor also  have  been  shown  to  occur in  the  central 
nervous system (40). CNTF was even proposed to act as an 
endogenous  pyrogen  in  rabbits  (41),  yet  none  of these 
IL-6-related cytokines seems to compensate for lack of ex- 
pression of IL-6 in the fever response. 
In summary, using mice with null mutation in the IL-6 
gene, we could demonstrate that central expression of IL-6 
is  a  necessary  component  of the  febrile  response  to  both 
LPS and IL-113. Furthennore~ it appears that neither TNF-cx 
nor IL-113 can bypass central IL-6 in production of the fe- 
ver response to LPS or IL-113 in mice. 
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